Published On: Fri, Sep 16th, 2016

Intellia Therapeutics Inc (NTLA) Sees Unusually-High Trading Volume

Intellia Therapeutics Inc (NASDAQ:NTLA) saw strong trading volume on Thursday . 288,620 shares changed hands during trading, an increase of 19% from the previous session’s volume of 243,376 shares.The stock last traded at $19.75 and had previously closed at $20.39.
A number of analysts have recently weighed in on the company. Jefferies Group reissued a “buy” rating and set a $33.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, August 17th. Leerink Swann began coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective for the company. Wedbush began coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 target price for the company. Zacks Investment Research downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. Finally, Credit Suisse Group AG began coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $35.50.
The firm’s market capitalization is $710.54 million. The company’s 50-day moving average price is $20.10 and its 200 day moving average price is $22.60.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/intellia-therapeutics-inc-ntla-sees-unusually-high-trading-volume.html

Institutional investors have recently made changes to their positions in the company. GLG Partners LP bought a new position in shares of Intellia Therapeutics during the second quarter worth approximately $100,000. Pacad Investment Ltd. bought a new position in shares of Intellia Therapeutics during the second quarter worth approximately $117,000. Metropolitan Life Insurance Co. NY bought a new position in shares of Intellia Therapeutics during the second quarter worth approximately $190,000. Teachers Advisors Inc. bought a new position in shares of Intellia Therapeutics during the second quarter worth approximately $235,000. Finally, Marshall Wace LLP bought a new position in shares of Intellia Therapeutics during the second quarter worth approximately $244,000.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Receive News & Ratings for Intellia Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>